syedzayyan/paper_mill_benchmark huggingface dataset:
Label-Free Proteomics Revealed Oxidative Stress and Inflammation as Factors That Enhance Chemoresistance in Luminal Breast Cancer.

Breast cancer is the leading cause of cancer-associated death among women worldwide.Its high mortality rate is related to resistance towards chemotherapies, which is one of the major challenges of breast cancer research.In this study, we used label-free mass spectrometry- (ms-) based proteomics to investigate the differences between circulating proteins in the plasma of patients with chemoresponsive and chemoresistant luminal a breast cancer.Ms analysis revealed 205 differentially expressed proteins.Furthermore, we used in silico tools to build protein-protein interaction networks.Most of the upregulated proteins in the chemoresistant group were closely related and tightly linked.The predominant networks were related to oxidative stress, the inflammatory response, and the complement cascade.Through this analysis, we identified inflammation and oxidative stress as central processes of breast cancer chemoresistance.Furthermore, we confirmed our hypothesis by evaluating oxidative stress and performing cytokine profiling in our cohort.The connections among oxidative stress, inflammation, and the complement system described in our study seem to indicate a pivotal axis in breast cancer chemoresistance.Hence, these findings will have significant clinical implications for improving therapies to bypass breast cancer chemoresistance in the future.

Journal: Oxidative medicine and cellular longevity (2019)
Publication types: Clinical Trial;Journal Article;Multicenter Study
NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injury.

Acute kidney injury (aki) with maladaptive tubular repair leads to renal fibrosis and progresses to chronic kidney disease (ckd).At present, there is no curative drug to interrupt aki-to-ckd progression.The nuclear factor of the activated t cell (nfat) family was initially identified as a transcription factor expressed in most immune cells and involved in the transcription of cytokine genes and other genes critical for the immune response.Nfat2 is also expressed in renal tubular epithelial cells (rtecs) and podocytes and plays an important regulatory role in the kidney.In this study, we investigated the renoprotective effect of 11r-vivit, a peptide inhibitor of nfat, on renal fibrosis in the aki-to-ckd transition and the underlying mechanisms.We first examined human renal biopsy tissues and found that the expression of nfat2 was significantly increased in rtecs in patients with severe renal fibrosis.We then established a mouse model of aki-to-ckd transition using bilateral ischemia-reperfusion injury (bi-iri).The mice were treated with 11r-vivit (5 mg/kg, i.p.) on days 1, 3, 10, 17 and 24 after bi-iri.We showed that the expression of nfat2 was markedly increased in rtecs in the aki-to-ckd transition.11r-vivit administration significantly inhibited the nuclear translocation of nfat2 in rtecs, decreased the levels of serum creatinine and blood urea nitrogen, and attenuated renal tubulointerstitial fibrosis but had no toxic side effects on the heart and liver.In addition, we showed that 11r-vivit administration alleviated rtec apoptosis after bi-iri.Consistently, preapplication of 11r-vivit (100 n m) and transfection with nfat2-targeted si rna markedly suppressed tgfβ-induced hk-2 cell apoptosis in vitro.In conclusion, 11r-vivit administration inhibits iri-induced nfat2 activation and prevents aki-to-ckd progression.Inhibiting nfat2 may be a promising new therapeutic strategy for preventing renal fibrosis after ir-aki.

Journal: Acta pharmacologica Sinica (2022)
Publication types: Journal Article
Diabetes and cardiovascular disease risk screening model in community pharmacies in a developing primary healthcare system: a feasibility study.

S this study aimed to develop an evidence-based community pharmacist-delivered screening model for diabetes and cardiovascular disease (cvd), and assess its feasibility to identify and refer patients with elevated risk.Design a feasibility study.Setting a purposive sample of 12 community pharmacies in three cities in the united arab emirates (uae).Participants adults 40 years of age and above who have not been previously diagnosed with either diabetes or cvd.Intervention pharmacist screening of adults visiting pharmacies involved history, demographics, anthropometric measurements, blood pressure and point-of-care testing including glycated haemoglobin (hb a1c) levels and lipid panel.Participants with a 10-year cvd risk ≥7.5%, hb a1c level ≥5.7% or american diabetes association (ada) risk score ≥5 points were advised to visit their physician.Primary and secondary outcome measures the primary outcomes were (1) development of uae pharmacist-delivered screening model, (2) the proportion of screened participants identified as having high cvd risk (atherosclerotic cvd 10-year risk defined as ≥7.5%) and (3) the proportion of participants identified as having elevated blood glucose (high hb a1c level ≥5.7% (38.8 mmol/mol)) or high self-reported diabetes risk (ada risk score ≥5 points).Secondary outcome is participants' satisfaction with the screening.Results the first uae pharmacist-delivered screening model was developed and implemented.A total of 115 participants were screened, and 92.3% of the entire screening process was completed during a single visit to pharmacy.The mean duration of the complete screening process was 27 min.At-risk individuals (57.4%) were referred to their physicians for further testing, while 94.5% of participants were at least satisfied with their screening experience.Conclusions the community pharmacist-delivered screening of diabetes and cvd risk is feasible in the uae.The model offers a platform to increase screening capacity within primary care and provides an opportunity for early detection and treatment.However, pathways for the integration of the pharmacist-delivered screening service with physicians in primary care are yet to be explored.

Journal: BMJ open (2019)
Publication types: Journal Article;Research Support, Non-U.S. Gov't
Return to Work, Demographic Predictors, and Symptomatic Analysis Among Healthcare Workers Presenting for COVID-19 Testing: A Retrospective Cohort From a United States Academic Occupational Medicine Clinic.

Introduction we sought to determine time to return to work (rtw) among healthcare workers (hcws) with mild/moderate coronavirus disease 2019 (covid-19) and identify predictors of covid-19 test positivity and illness duration.Methods a retrospective review of hcws presenting for covid-19 testing/evaluation in december 2020 was performed to examine demographics, clinical characteristics, and rtw.Results of 250 exposure incidents, 107 employees (42.80%) tested positive for severe acute respiratory syndrome coronavirus 2 (sars-co v-2).No significant differences between covid-19 positive and negative hcws were noted in terms of key demographics, including age, gender, and cdc risk scores.Cough (77.57% vs 56.64%, p = 0.001), fatigue (66.36% vs 51.05%, p = 0.015), fever/chills (65.42% vs 37.06%, p < 0.001), myalgia (57.01% vs 35.66%, p = 0.008), and change in smell/taste (38.32% vs 13.29%, p < 0.001) were more prevalent among covid-19 positive versus negative hcws.Change in smell/taste (p < 0.001, or 3.592), cough (p = 0.001, or 2.966), and fever/chills (p = 0.019, or 2.107) were independently associated with covid-19 test positivity.Mean time to rtw from symptom onset was 13.09 days for covid-19 positive hcws.Female gender (p = 0.020, + 3.20 days), older age (p = 0.014, + 2.22 days), and myalgia (p = 0.021, + 2.23 days) were predictive of longer illness duration.Conclusion change in taste/smell, cough, and fever/chills were independently associated with covid-19 test positivity.Among hcws with mild/moderate covid-19 infection, the mean time to rtw was approximately 13 days with female gender, older age, and myalgia being predictive of delayed rtw.

Journal: Cureus (2021)
Publication types: Journal Article
A Feasibility Study for 3D-printed Poly(methyl methacrylate)-resin Tracheostomy Tube Using a Hamster Cheek Pouch Model.

/aim a three-dimensional (3d) printed tracheostomy tube has potential application for patients who require a specialized tube.The aim of this study was to evaluate the characteristics of various 3d printing materials and determine their use in producing 3d-printed tracheostomy tube.Materials and methods mechanical, chemical, and microbiological in vivo changes in the scaffolds were analyzed using a hamster cheek pouch (hcp) model.Results the poly methyl methacylate (pmma)-resin showed superior pre- and post-insertion mechanical properties and a relatively consistent lower biofilm formation compared with other scaffolds.Pmma-resin was successfully 3d-printed with dimensional accuracy without a support system.The use of a 3d-printed pmma tracheostomy tube in a rabbit trachea showed no definite signs of infection, allergy or foreign body reaction.Conclusion pmma-resin can be proposed as an alternative for a 3d-printed tracheostomy tube material.In addition, we suggest hcps as an in vivo model for evaluating indwelling medical devices.

Journal: In vivo (Athens, Greece) (2020)
Publication types: Journal Article
Study on emergency evacuation in underground urban complexes.

With progressive urbanization and the development and utilization of urban underground space, underground urban complexes (uucs) have been increasingly used.Uucs have brought much convenience to people's lives.However, due to their enclosed nature and complexity, it has been an urgent issue to avoid (or reduce) casualties and allow rapid and safe evacuation of people during an emergency.In this study, the evacuation simulation software pathfinder was used.Based on the steering model, the variation of the total evacuation time and pedestrian flow at main exits with different simulated evacuation measures, congestion at key nodes and people's path selection were compared and analyzed.Then, the critical locations in the spatial layout of uucs that were prone to evacuation bottleneck effects were focused on and determined.The evacuation effectiveness of uucs in an emergency was studied to investigate the problems of emergency evacuation in uucs.It is found that in uucs, the bottleneck effects were likely to occur at stairway entrances and exits as well as supermarket checkout counters and caused severe congestion.These locations should be focused on during emergency evacuation.For key locations prone to evacuation bottlenecks, increasing the width of exits or setting up auxiliary evacuation channels could be an effective measure to improve evacuation efficiency.In addition, formulating rational evacuation rules can be a favorable measure for emergency evacuation.However, during the evacuation, the herd mentality in people has an uncertain (positive or negative) impact on evacuation effectiveness.Setting up diversion walls may improve evacuation efficiency and reduce congestion to a certain extent, while evacuation confusion and chaos are prone to occur after diversion.These findings in this study have significant implications for improving the emergency management of uucs.

Journal: PloS one (2022)
Publication types: Journal Article
Is there a place for Traditional Chinese Medicine (TCM) in the treatment of recurrent pregnancy loss?

Recurrent pregnancy loss (rpl) impacts a couple's quality of life, mental health and constitutes a large economic burden for care.Traditional chinese medicine (tcm) is an integrated systematic medical practice with wide clinical applications that has been predominantly used throughout asian countries for over 2000 years.However, the efficacy of tcm in the treatment of rpl remains unclear due not only to a lack of experimental evidence, but also a lack of comprehensive summarized conclusions.Therefore, the current manuscript reviews recent relevant publications of the clinical use of tcm in rpl and illustrates its potential mechanisms.All publications (in both chinese and english), especially randomized controlled trials (rcts), on the use of tcm in rpl for the last ten years and research on its mechanisms were included.This review also describes our understanding of the problems and challenges in the modernization of tcm research.

Journal: Journal of reproductive immunology (2022)
Publication types: Journal Article;Review;Research Support, Non-U.S. Gov't
Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.

The purpose of this article is to review the pharmacological characteristics and clinical evidence of oral semaglutide for the treatment of type 2 diabetes mellitus (t2dm).data sources:a medline/pub med search was conducted between january 1, 2005, and september 30, 2019.Search terms includedsemaglutide, glucagon-like peptide 1 receptor agonist, glp-1 receptor agonist, andtype 2 diabetes.study selection and data extraction quantification:the following study designs were included in the analysis: systematic review and/or meta-analyses, clinical trial, or observational study design.Narrative reviews were excluded.Articles were included only if they were published in the english language or evaluated oral semaglutide with regard to pharmacology, pharmacokinetics, safety, and efficacy in humans.data synthesis:oral semaglutide has been food and drug administration approved for the treatment of t2dm as an adjunct to diet and exercise.Oral semaglutide has been shown to result in an absolute hemoglobin a1creduction between -0.5% and -1.5% and weight reductions between -1 and -4.7 kg.Oral semaglutide has been shown to be noninferior to placebo for cardiovascular (cv) safety although additional cv outcomes trials are ongoing.Adverse effects appear to be similar to those of other glucagon-like peptide-1 receptor agonists and are gastrointestinal in nature.relevance to patient care and clinical practice:oral semaglutide may be appropriate as second- or third-line add-on therapy for patients with t2dm who are not meeting treatment goals on metformin and are overweight and reluctant to use an injectable drug.conclusions:oral semaglutide appears safe and effective as monotherapy and add-on pharmacological therapy for the treatment of t2dm.

Journal: The Annals of pharmacotherapy (2020)
Publication types: Journal Article;Review
Past medical history of tumors other than meningioma is a negative prognostic factor for tumor recurrence in meningiomas WHO grade I.

Prognostic markers for meningioma recurrence are needed to guide patient management.Apart from rare hereditary syndromes, the impact of a previous unrelated tumor disease on meningioma recurrence has not been described before.Methods we retrospectively searched our database for patients with meningioma who grade i and complete resection provided between 2002 and 2016.Demographical, clinical, pathological, and outcome data were recorded.The following covariates were included in the statistical model: age, sex, clinical history of unrelated tumor disease, and localization (skull base vs.Convexity).Particular interest was paid to the patients' past medical history.The study endpoint was date of tumor recurrence on imaging.Prognostic factors were obtained from multivariate proportional hazards models.Results out of 976 meningioma patients diagnosed with a meningioma who grade i, 416 patients fulfilled our inclusion criteria.We encountered 305 women and 111 men with a median age of 57 years (range: 21-89 years).Forty-six patients suffered from a tumor other than meningioma, and no tert mutation was detected in these patients.There were no differences between patients with and without a positive oncological history in terms of age, tumor localization, or mitotic cell count.Clinical history of prior tumors other than meningioma showed the strongest association with meningioma recurrence (p = 0.004, hr = 3.113, ci = 1.431-6.771) both on uni- and multivariate analysis.Conclusion past medical history of tumors other than meningioma might be associated with an increased risk of meningioma recurrence.A detailed pre-surgical history might help to identify patients at risk for early recurrence.

Journal: Acta neurochirurgica (2021)
Publication types: Journal Article
Patients with non-idiopathic sudden sensorineural hearing loss show hearing improvement more often than patients with idiopathic sudden sensorineural hearing loss.

Introduction to compare inpatient treated patients with idiopathic (issnhl) and non-idiopathic sudden sensorineural hearing loss (nissnhl) regarding frequency, hearing loss, treatment and outcome.Methods all 574 inpatient patients (51% male, median age: 60 years) with issnhl and nissnhl, who were treated in federal state thuringia in 2011 and 2012, were included retrospectively.Univariate and multivariate statistical analyses were performed.Results issnhl was diagnosed in 490 patients (85%), nissnhl in 84 patients (15%).49% of these cases had hearing loss due to acute otitis media, 37% through varicella-zoster infection or lyme disease, 10% through menière disease and 7% due to other reasons.Patients with issnhl and nissnhl showed no difference between age, gender, side of hearing loss, presence of tinnitus or vertigo and their comorbidities.45% of patients with issnhl and 62% with nissnhl had an outpatient treatment prior to inpatient treatment (p < 0.001).The mean interval between onset of hearing loss to inpatient treatment was shorter in issnhl (7.7 days) than in nissnhl (8.9 days; p = 0.02).The initial hearing loss of the three most affected frequencies in pure-tone average (3ptamax) scaled 72.9 d bhl ± 31.3 d bhl in issnhl and 67.4 d bhl ± 30.5 d bhl in nissnhl.In the case of acute otitis media, 3ptamax (59.7 d bhl ± 24.6 d bhl) was lower than in the case of varicella-zoster infection or lyme disease (80.11 d bhl ± 34.19 d bhl; p = 0.015).Mean absolute hearing gain (δ3ptamaxabs) was 8.1 d b ± 18.8 d b in patients with issnhl, and not different in nissnhl patients with 10.2 d b ± 17.6 d b.A δ3ptamaxabs≥ 10 d b was reached in 34.3% of the patients with issnhl and to a significantly higher rate of 48.8% in nissnhl patients (p = 0.011).Conclusions issnhl and nissnhl show no relevant baseline differences.Issnhl tends to have a higher initial hearing loss.Nisshnl shows a better outcome than issnhl.

Journal: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2022)
Publication types: Journal Article
Systematic review of outcomes in studies of reproductive genetic carrier screening: Towards development of a core outcome set.

Current practice recommendations support the widespread implementation of reproductive genetic carrier screening (rgcs).These consensus-based recommendations highlight a research gap, with findings from current studies being insufficient to meet the standard required for more rigorous evidence-based recommendations.This systematic review assessed methodological aspects of studies on rgcs to inform the need for a core outcome set.Methods we conducted a systematic search to identify peer-reviewed published studies offering population-based rgcs.Study designs, outcomes, and measurement methods were extracted.A narrative synthesis was conducting using an existing outcome taxonomy and criteria used in the evaluation of genetic screening programs as frameworks.Results sixty-five publications were included.We extracted 120 outcomes representing 24 outcome domains.Heterogeneity in outcome selection, measurement methods and time points of assessment was extensive.Quality appraisal raised concerns for bias.We found that reported outcomes had limited applicability to criteria used to evaluate genetic screening programs.Conclusion despite a large body of literature, diverse approaches to research have limited the conclusions that can be cumulatively drawn from this body of evidence.Consensus regarding meaningful outcomes for evaluation of rgcs would be a valuable first step in working towards evidence-based practice recommendations, supporting the development of a core outcome set.

Journal: Genetics in medicine : official journal of the American College of Medical Genetics (2022)
Publication types: Journal Article;Research Support, Non-U.S. Gov't;Review;Systematic Review
Captivity and geography influence the antibiotic resistome of non-human primates.

Introduction antibiotic resistance poses a serious threat for animals and humans health worldwide.Yet a comprehensive exploration of the influence of captivity and geography on non-human primate (nph) gut antibiotic resistance remains incomplete.Methods in this study, 131 metagenomic sequencing datasets of five species of nhps included different regions and lifestyles were selected to perform the antibiotic resistance analysis.Results nineteen related resistance antibiotics and 325 antibiotic resistance genes (args) were obtained.A significantly higher abundance and diversity index of args in the captive nhps than in the wild was found but not for all of the samples.The biomarker-tracking of args analysis identified key args related to aminoglycoside resistance genes and tetracycline resistance genes.Discussion these results suggest that captivity and geography changes associated with human activities can lead to marked changes in the ecology of the nhp gut flora args.

Journal: Frontiers in veterinary science (2022)
Publication types: Journal Article
Application of immunomodulatory therapy in a human brucellosis patient with pancytopenia: A case report.

Brucellosis is a common zoonotic infectious disease with diverse and non-specific clinical manifestations caused by brucella.although brucellacan cause damage to multiple systems in the human body, hematological complications are relatively rare.We present a case of a 47-year-old male brucellosis patient with pancytopenia.In may 2018, the patient was diagnosed with brucellosis and recovered after receiving antibiotic treatment (rifampicin 600 mg/day and doxycycline 200 mg/day) for six weeks.However, after three years, the patient experienced a recurring high fever.Brucellosis relapse was confirmed based on the patient's clinical history, rose bengal plate agglutination test and standard tube agglutination test results.Routine blood examination revealed a decrease in the whole blood cell count, suggesting bone marrow suppression.Bone marrow aspiration and bacterial culture confirmed the diagnosis of brucellosis with pancytopenia.Antibiotic treatment failed to effectively improve the patient's condition.Therefore, a combination of immunomodulatory and antibiotic treatments was used.The antibiotic regimen included oral rifampicin 600 mg/day, intravenous doxycycline hydrochloride 200 mg/day, and subcutaneous injection of human granulocyte-stimulating factor (0.2 mg/day).Immunomodulatory therapy consisted of 20,000 mg/day intravenous human immunoglobulin (p h 4) for five days and 800 mg/day oral pidotimod liquid for 20 days.As the treatment progressed, the count gradually recovered to normal levels, and the symptoms of bone marrow suppression were alleviated.Pcr testing revealed the absence of brucella dna in both monocyte and serum samples.Furthermore, negative standard tube agglutination test results were obtained.These findings indicate that the immunomodulatory therapy resulted in a complete clearance of brucella.therefore, immunomodulatory therapy could be an effective option in cases of brucellosis with pancytopenia that are unresponsive to conventional antibiotic treatment.Further research and clinical evidence are required to confirm and optimize the use of immunomodulatory therapies in patients with brucellosis.

Journal: Heliyon (2023)
Publication types: Case Reports;Journal Article